Youwen H. Zhu
Changsha, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 49 publications
The clinical value of adding immune checkpoint inhibitors to radiotherapy for cancer: a systematic review and meta-analysis.
Journal: Annals of medicine
Published: August 19, 2026
Comprehensive Comparison of Surgery Followed by Radiotherapy and Radical Radiotherapy for Cervical Cancer: A Multicenter Retrospective Propensity-Score-Matched Analysis.
Journal: Cancers
Published: February 09, 2026
Association Between Maternal Diabetes and the Risk of Cancers in Mother-Offspring: A Meta-Analysis of 44.9 Million Pregnancies.
Journal: Diabetes, obesity & metabolism
Published: February 04, 2026
Global, regional, and national burdens of human papillomavirus-associated cervical cancer attributable to sexually acquired human papillomavirus infections among individuals aged 10-54 years from 1990 to 2021: findings from the Global Burden of Disease study 2021.
Journal: Sexual medicine
Published: February 04, 2026
Pooled survival and cost-effectiveness analysis of immune checkpoint inhibitors-based for metastatic non-small-cell lung cancer with PD-L1 lower than 1.
Journal: Health economics review
Published: December 14, 2025
Tumor treating field plus chemotherapy for locally advanced pancreatic adenocarcinoma: An international cost-effectiveness analysis.
Journal: Scientific reports
Published: November 20, 2025
Immune checkpoint inhibitors-based therapies for first-line treatment of advanced ovarian cancer with non-BRCAm/HRD-negative: a cost-effectiveness analysis.
Journal: Journal of ovarian research
Published: September 22, 2025
Treatment-related adverse events of CD3-based T cell-engaging bispecific antibodies in patients with cancer: a meta-analysis of clinical trials.
Journal: The Lancet. Oncology
Published: August 27, 2025
Targeting epigenetic methylation: emerging diagnosis and therapeutic strategies in cancer.
Journal: Experimental hematology & oncology
Published: August 01, 2025
International Cost-Effectiveness Analysis of Nivolumab Versus Brentuximab Vedotin for Patients With Advanced-Stage Classic Hodgkin's Lymphoma.
Journal: Hematological oncology
Published: July 31, 2025
Pembrolizumab plus chemotherapy followed by maintenance with or without olaparib as first-line treatment for advanced BRCAwt ovarian cancer with LOH-low: a international cost-effectiveness analysis.
Journal: Journal of ovarian research
Published: July 12, 2025
International cost-effectiveness analysis of durvalumab consolidation treatment after chemoradiotherapy for patients with limited-stage small-cell lung cancer.
Journal: Translational lung cancer research
Published: March 24, 2025
Last Updated: 09/26/2026